Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of RNA medicines.
July 10, 2019
Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference
June 27, 2019
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
June 19, 2019
Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases